Showing results (251-260 of 319) with videos related to
Sort By:
Pageof 32
Journal of Neurology, Neurosurgery, and Psychiatry|April 21, 1999
The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseasesH R Morris, J C Janssen, O Bandmann, et al.Clinical Neuropharmacology|October 1, 1989
A double-blind, controlled study of high-dose L-deprenyl in the treatment of Parkinson's diseaseJ P Frankel, P A Kempster, C M Stibe, et al.Journal of Neurochemistry|September 1, 1997
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigraZ I Alam, A Jenner, S E Daniel, et al.Annals of Neurology|September 1, 1994
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal gangliaJ Sian, D T Dexter, A J Lees, et al.Neuroscience Letters|October 12, 2001
Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophyH R Morris, A Schrag, U Nath, et al.Neuroscience|May 1, 1995
Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's diseaseA P Nisbet, O J Foster, A Kingsbury, et al.Lancet (London, England)|October 15, 1977
Deprenyl in Parkinson's diseaseA J Lees, K M Shaw, L J Kohout, et al.Annals of Neurology|July 1, 1991
Dopa-responsive dystonia: [18F]dopa positron emission tomographyG V Sawle, K L Leenders, D J Brooks, et al.Lancet (London, England)|September 8, 1990
Neurological deterioration in young adults with phenylketonuriaA J Thompson, I Smith, D Brenton, et al.Lancet (London, England)|December 24, 1988
Role of subcutaneous apomorphine in parkinsonian voiding dysfunctionT J Christmas, P A Kempster, C R Chapple, et al.Pageof 32